|
02 Feb 2020 |
CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes
|
|
02 Feb 2020 |
Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities
|
|
31 Jan 2020 |
Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill™
|
|
30 Jan 2020 |
Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis
|
|
30 Jan 2020 |
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
|
|
28 Jan 2020 |
Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease
|
|
27 Jan 2020 |
Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery
|
|
27 Jan 2020 |
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
|
|
27 Jan 2020 |
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
|
